ARI 
 JRI 
 ISERB 
blogger delicious digg diigo facebook googleplus linkedin netlog reddit twitter
Skip Navigation LinksJRI > Archive > April-June 2007, Volume 8, Issue 1 > Determining the prevalence, risk factors and management of borderline ovarian tumors



Volume 8, Issue 1, Number 30 / April-June
(pages 38-44)


Determining the prevalence, risk factors and management of borderline ovarian tumors




 Corresponding Author
Department of Obs. & Gyn, Faculty of Medicine, Mashad University of Medical Sciences, Mashad, Iran

Department of Obs. & Gyn, Faculty of Medicine, Mashad University of Medical Sciences, Mashad, Iran

Department of Oncology, Faculty of Medicine, Mashad University of Medical Sciences, Mashad, Iran

Department of Biostatistics, Faculty of Medicine, Mashad University of Medical Sciences, Mashad, Iran


Related Articles
in Google Scholar in PubMed

 

Other Format
pdfPDF Full Text (En) pdfPDF Full Text (Fa) pdfePUB Full Text (En) pdfPDF Abstract (En) pdfPDF Abstract (Fa) pdf BibTeX pdfRefMan pdfEndNote xmlPMC XML online readerPMC Reader

 


Abstract
Introduction: Approximately 10-15% of all epithelial ovarian tumors fall into the category of low malignant potential tumors (Borderline ovarian tumors) which tend to be confined to the ovary for a long period. Biologically, these tumors have low aggressive behavior and malignant potentials, therefore, early diagnosis, recognition of the signs and symptoms and management of these patients is of significant importance. The purpose of this study was to determine the preva-lence, evaluate some risk factors and discuss the management of patients with borderline ovarian tumors. Materials & Methods: This descriptive analytical retrospective study was performed on the medical files of 132 patients with ovarian epithelial cancers who had referred to the oncology departments of Ghaem and Omid Hospitals of Mashad University of Medical Sciences from 1994 to 2003. A questionnaire comprising of demographic data was filled for each patient. Statistical analysis was done by a computer using SPSS software for the calculation of t-test and 2. The confidence interval was regarded 95%, while p<0.05 was considered significant. Results: 16.6% of the patients had borderline ovarian tumors. The mean age of the patients was 25.07±3.25 SD years. The most common pathological type of tumor was borderline mucinous cystadenoma (71.3%). The majority of patients were in stage I of the disease (78.4%). Elevated CA-125 tumor marker was discovered in 42.1% of the patients. Conservative surgical manage-ment was performed in 42.1% and radical surgery for the rest of the patients. Recurrence had been seen in 21.3% of the patients. 21.3% of the patients had died because of extraovarian dissemination of the disease. Conclusion: Borderline ovarian tumors are almost associated with good prognosis but because of probable recurrence and death, post-treatment serial follow-ups of these patients are recom-mended.

Keywords: Borderline ovarian tumor, Invasive epithelial ovarian cancer, Prognosis, Recurrence, Prevalence, Tumor marker, Disease stage, Conservative management, Chemotherapy


To cite this article:


References
  1. Seracchioli R, Venturoli S, Colombo FM, Govoni F, Missiroli S, Bagnoli A, M.D. Fertility and tumor recur-rence rate after conservative laparoscopic management of young women with early-stage borderline ovarian tumors. Fertil Steril. 2001;76(5):999-1004.   [PubMed]
  2. Idotta R, Scopelliti P, Polimeni C, Lirosi MF. Serous papillary cystic ovarian borderline tumor: case report. Clin Exp Obstet Gynecol. 2002;29(4):293-6.   [PubMed]
  3. Mikami M, One A, Sakaiya N, Kurahashi T, Komi-yama S, Komuro Y. Case report of serous ovarian tumor of borderline malignancy (Stage Ic) in a preg-nant woman. Eur J Obstet Gynecol Reprod Biol. 2001; 98(2):237-9.   [PubMed]
  4. Vine MF, Ness RB, Calingaert B, Schildkraut JM, Berchuck A. Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. Gynecol Oncol. 2001;83(3):466-71.   [PubMed]
  5. Moreira AL, Yao J, Waisman J, Cangiarella JF. Metas-tatic borderline papillary ovarian tumor in an intrama-mmary lymph node. Breast J. 2002;8(5):309-10.   [PubMed]
  6. Kaern J, Trope CG, Abeler VM, Abeler VM. A retros-pective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer. 1993;71:1810-20.   [PubMed]
  7. Camatte S, Morice P, Atallah D, Pautier P, Lhomme C, Haie-Meder C, Duvillard P, Castaigne D. Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an ana-lysis of a series of 42 lymphadenectomies. J Am Coll Surg. 2002;195(3):332-8.   [PubMed]
  8. Battaglia F, Plotti F, Zullo MA, Panici PB, Plotti G. Successful pregnancy after conservative sutgery for stage IC ovarian cancer with serous borderline tumor on controlateral ovary: A case report. Gynecol Oncol. 2005;(21):465-71.   [PubMed]
  9. Schilder JM, Thompson AM, Depriest PD, Ueland FR, Cibull ML, Kryscio RJ, et al. Outcome of repro-ductive age women with stage IA or IC invasive epi-thelial ovarian cancer treated with fertility-sparing the-rapy. Gynecol Oncol. 2002;87(1):1-7.   [PubMed]
  10. Goff BA, Mandel L, Muntz HG, Melacon CH, Ova-rian cancer diagnosis results of a national ovarian can-cer surgery. Cancer. 2000;89:2068-75.
  11. Verness B, Elnbibakh GH. Familial ovarian cancer and early ovarian cancer biologic, pathologic and clini-cal features. Int J Gynecol Pathol. 2001;(20):48-63.   [PubMed]
  12. Li CC, Hirokawa M, Qian Z, Fujii Y, Ino H, Wakat-suki S, Horiguchi H, Kagawa N, Sano T. Morules with optically clear nuclei in ovarian borderline endomet-rioid tumor. APMIS. 2002;110(11): 783-8.   [PubMed]
  13. Kir G, Eren S, Kir M. Hyperplastic mesothelial cells in pelvic and abdominal lymph node sinuses mimi-cking metastatic ovarian microinvasive serous border-line tumor. Eur J Gynecol Oncol. 2004;25(2):236-8.   [PubMed]
  14. Yuen PM. Wound recurrence by implantation of a borderline ovarian tumour following laparoscopic removal . Br J Obstet Gynecol. 1994;101:1026-7.   [PubMed]
  15. Parker RL, Clement PB, Chercover DJ, Sornarajah T, Gilks CB. Early recurrence of ovarian serous border-line tumor as high-grade carcinoma: a report of two cases. Int J Gynecol Pathol. 2004;23(3):265-72.   [PubMed]
  16. Canis M, Mage G, Pouly JL, Wattiez A, Mannes H, Bruhat MA. Laparoscopic diagnosis of adnexal cystic masse: a 12-year experience with long-term follow-up. Obstet Gynecol. 1994;83:707-12.   [PubMed]
  17. Lim Tan SK, Cajiagas HE, Scully R. Ovarian cystic-tomy for serous borderline tumors: a follow-up study of 35 cases. Obstet Gynecol. 1988;72:775-80.   [PubMed]
  18. Trope C, Vergote JB, Kristensen G, Kristensen G, Abeler V. Are borderline tumors of the ovary over-treated both surgically and systemically?. A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol. 1993; 51:236-43.
  19. Engelen MJ, Bruijn HW, Hollema H, Hoor KA, Wil-lemse PH, Aalders JG, Serum CA 125, carcino-embryonic antigen, and CA19-9 as tumor markers in borderline ovarian tumors. Gynecolo Oncol. 2000;78 (1):16-20.   [PubMed]
  20. Link CJ Jr, Kohn E, Reed E, Review the relationship between borderline ovarian tumors and epithelial ova-rian carcinoma: epidemiologic, Pathologic and mole-cular aspects. Gynecol Oncol. 1996;60:347-54.   [PubMed]
  21. Gotlieb WH, Flikker S, Davidson B, Korach Y, Kop-polvic J, BenBaruch G. Borderline tumors of the ovary: Fertility treatment, conservative management and preg-nancy outcome. Cancer. 1998;82:141-6.   [PubMed]
  22. Seracchioli R, Venturoli S, Colombo FM, Govoni F, Missiroli S, Bagnoli A. Fertility and tumor recurrence rate after conservative laparoscopic management of young women with early-stage borderline ovarian tu-mors. Fertil Steril. 2001;76(5):999-1004.   [PubMed]
  23. Morice P, Thoury A, Sabourin JC, Camatte S, Atallah D, Armand JP, Madelenat P, Duvillard P, Castaigne D. Case 2. Spontaneous regression of peritoneal implants in borderline ovarian tumor after salpingo-oophorec-tomy. J Clin Oncol. 2003;15;21(18):3536-8.   [PubMed]
  24. Morris RT, Gershenson DM, Silva EG, Follen M, Morris M, Wharton JT. Outcome and reproductive function after conservative sutgery for borderline ova-rian tumors. Obstet Gynecol. 2000;95:541-7.   [PubMed]
  25. Chamberlin MD, Eltabbakh GH, Mount SL, Leavitt BJ. Metastatic serous borderline ovarian tumor in an internal mammary lymph node: a case report and review of the literature. Gynecol Oncol. 2001;82(1): 212-5.   [PubMed]
  26. Battaglia F, Plotti F, Zullo MA, Panici BP Plotti G. Successful pregnancy after conservative sutgery for stage IC ovarian cancer with serous borderline tumor on controlateral ovary: A case report. Gynecol Oncol. 2005;(6)463-471.   [PubMed]
  27. Lobo RA. Potential options for preservation of ferti-lity in women. N Engl J Med. 2005;353(1):64-73.   [PubMed]
  28. Papadimitrou DS, Martin-Hirsch P, Kitchener HC, Lolis DE, Dalkalitsis N, Paraskevaidis E. Recurrent borderline ovarian tumours after conservative manage-ment in women wishing to retain their fertility. Eur J Gynecol Oncol. 1999;2:94-7.   [PubMed]
  29. Longacre TA, Mckenney JK, Tazelaer Hb. Ovarian serous tumors of low malignant (borderline tumors). Outcome-based study of 276 patients with long term follw-up. Am J Surg Pathol. 2002;29(6):707-23.   [PubMed]



Home | About Us | Current Issue | Past Issues | Submit a Manuscript | Instructions for Authors | Subscribe | Search | Contact Us

"Journal of Reproduction & Infertility" is owned, published, and copyrighted by Avicenna Research Institute .
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Journal of Reproductoin and Infertility (JRI) is a member of COMMITTEE ON PUBLICATION ETHICS . Verify here .

©2016 - eISSN : 2251-676X, ISSN : 2228-5482, For any comments and questions please contact us.